Form 4: Singular Genomics CFO Dalen Meeter Reports Stock Transactions
SEC Form 4 Filing
Chief Financial Officer Dalen Meeter of Singular Genomics Systems, Inc. reports the acquisition of 500 shares of common stock through the settlement of vested Restricted Stock Units (RSUs) on August 9, 2024.
Summary
- Dalen Meeter, CFO of Singular Genomics Systems, Inc., filed a Form 4 on August 13, 2024, reporting changes in beneficial ownership.
- On August 9, 2024, Meeter acquired 500 shares of Common Stock through the vesting of Restricted Stock Units (RSUs).
- Following the transaction, Meeter directly owns 7,984 shares of Common Stock.
- The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on June 26, 2024.
- The RSUs vest in 16 equal quarterly installments over four years, starting from February 9, 2024.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reporting stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The filing provides transparency to shareholders regarding executive stock ownership.
Key Dates
| Date | Description |
|---|---|
| February 9, 2024 | Date from which RSUs vest in 16 equal quarterly installments over four years |
| June 26, 2024 | Date of the 1-for-30 reverse stock split |
| August 9, 2024 | Date of transaction: acquisition of 500 shares through RSU settlement |
| August 13, 2024 | Date Form 4 was signed |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.